Study Title

A Phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. (GOG 3059)

Purpose

To evaluate the effect of AVB-S6-500 plus Paclitaxel versus placebo and Paclitaxel on progression-free survival based on response evaluation criteria in solid tumors criteria, in subjects with platinum-resistant ovarian cancer.

Eligibility

Study Process